Andreu-Sanz, D.* et al. Predictive value of preclinical models for CAR-T cell therapy clinical trials: A systematic review and meta-analysis. J. Immunother. Cancer 13:e011698 (2025)
Chen, W.L.* et al. Differential regulation of calcium-NFAT signaling pathway by Akt isoforms: Unraveling effector dynamics and exhaustion of cytotoxic T lymphocytes in tumor microenvironment. J. Immunother. Cancer 13:e009827 (2025)
Märkl, F.* et al. Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma. J. Immunother. Cancer 11:14 (2023)
Gottschlich, A.* et al. Single-cell transcriptomic atlas-guided development of chimeric antigen-receptor (CAR) T cells for the treatment of acute myeloid leukemia. J. Immunother. Cancer 10, A31-A31 (2022)
Mempel, T.R.* & Krappmann, D. Combining precision oncology and immunotherapy by targeting the MALT1 protease. J. Immunother. Cancer 10:e005442 (2022)
Stock, S.* et al. Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors. J. Immunother. Cancer 10:e005054 (2022)
Ahmetlic, F. et al. Therapy of lymphoma by immune checkpoint inhibitors: The role of T cells, NK cells and cytokine-induced tumor senescence. J. Immunother. Cancer 9:e001660 (2021)
Keller, P.* et al. Reprogramming regulatory T cells (TREG) using a MALT1 inhibitor for cancer therapy. J. Immunother. Cancer 9, A902-A902 (2021)
Baroni, M.L.* et al. 41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo. J. Immunother. Cancer 8:e000845 (2020)
Bauer, V. ; Ahmetlic, F. ; Roecken, M.* & Mocikat, R. Immune checkpoint blockade impacts the suppressive phenotype and function of regulatory T cells in an endogenous mouse lymphoma model. J. Immunother. Cancer 8, 3, A467-A468 (2020)
Gambichler, T.* ; Reuther, J.* ; Scheel, C. & Becker, J.C.* On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19. J. Immunother. Cancer 8:e001145 (2020)
Yanchun, M. et al. Interleukin-10 drives the development of T regulatory type 1 (Tr1) cells and is a target for immunotherapy. J. Immunother. Cancer 8, 3, A500 (2020)
Kuczek, D.E.* et al. Collagen density regulates the activity of tumor-infiltrating T cells. J. Immunother. Cancer 7:68 (2019)